SCHEMBL22816391

SCHEMBL22816391

O=C(O)c1[nH]nnc1Sc1cccc(OC2CCCCC2)c1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HAO1 Q9UJM8 16/20 0.45
▸ ITGB2 P05107 1/20 0.39
▸ ICAM1 P05362 1/20 0.39
▸ ITGAL P20701 1/20 0.39
▸ KAT6A Q92794 1/20 0.37
▸ MAOB P27338 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30631933 1.00 HAO1 (0.45) HAO1ITGB2ICAM1ITGALKAT6A
SCHEMBL22817013 0.99 HAO1 (0.44) HAO1ITGB2ICAM1ITGALKAT6A
SCHEMBL30631949 0.99 HAO1 (0.44) HAO1ITGB2ICAM1ITGALKAT6A
Trifluoroacetic Acid SCHEMBL22608635 0.94 HAO1 (0.41) HAO1ITGB2ICAM1ITGAL
Trifluoroacetic Acid SCHEMBL22608395 0.93 HAO1 (0.40) HAO1ITGB2ICAM1ITGAL
SCHEMBL22816389 0.86 TUBB4A (0.44) HAO1ITGB2ICAM1ITGALMAOB
SCHEMBL22817014 0.85 TUBB4A (0.45) HAO1ITGB2ICAM1ITGALMAOB
SCHEMBL22608636 0.84 ITGB2 (0.40) HAO1ITGB2ICAM1ITGALMEN1
SCHEMBL22608396 0.83 ITGB2 (0.39) HAO1ITGB2ICAM1ITGALKAT6A
SCHEMBL22608082 0.79 HAO1 (0.66) HAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117126152-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 — — CN disclosed
CN-117126151-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 — — CN disclosed
CN-117069713-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 — — CN disclosed
CN-117069712-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 — — CN disclosed
CN-117024420-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-10 — — CN disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 — — US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 — — US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT HAO1 9/4885ITGB2 4562/4885ICAM1 4050/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885ITGB2 4562/4885ICAM1 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback